Patent classifications
C07D207/08
Compositions for treating neurodegenerative diseases
The present disclosure relates to novel compounds of Formula I ##STR00001##
wherein each of R.sup.a, R.sup.b, R.sup.d and R.sup.e is independently H; R.sup.c is selected from the group consisting of H, hydroxyl, halo, alkyl, alkoxy, CF.sub.3, SO.sub.2CH.sub.3, and morpholino, R.sup.1 is selected from the group consisting of hydrogen, alkyl, phenyl, or CH?C(CH.sub.3).sub.2; and R.sup.2 is specific substituted cyclic amino groups. The invention also discloses pharmaceutical compositions containing the compounds and methods of using the compounds and pharmaceutical compositions for treating neurogenerative diseases, including Alzheimer's disease and cognitive decline.
Compositions for treating neurodegenerative diseases
The present disclosure relates to novel compounds of Formula I ##STR00001##
wherein each of R.sup.a, R.sup.b, R.sup.d and R.sup.e is independently H; R.sup.c is selected from the group consisting of H, hydroxyl, halo, alkyl, alkoxy, CF.sub.3, SO.sub.2CH.sub.3, and morpholino, R.sup.1 is selected from the group consisting of hydrogen, alkyl, phenyl, or CH?C(CH.sub.3).sub.2; and R.sup.2 is specific substituted cyclic amino groups. The invention also discloses pharmaceutical compositions containing the compounds and methods of using the compounds and pharmaceutical compositions for treating neurogenerative diseases, including Alzheimer's disease and cognitive decline.
HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS
Disclosed are compounds for treating or preventing a disease or disorder responsive to antagonism of a P2Y.sub.14R receptor agonist in a mammal in need thereof, for example, compounds of formulas (I) and (II), wherein R.sup.1.sub.-R.sup.8, X, Y, Z, X, Y, Z, and A are as defined herein, that are useful in treating an inflammatory such as asthma, cystic fibrosis, and sterile inflammation of the kidney.
##STR00001##
HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS
Disclosed are compounds for treating or preventing a disease or disorder responsive to antagonism of a P2Y.sub.14R receptor agonist in a mammal in need thereof, for example, compounds of formulas (I) and (II), wherein R.sup.1.sub.-R.sup.8, X, Y, Z, X, Y, Z, and A are as defined herein, that are useful in treating an inflammatory such as asthma, cystic fibrosis, and sterile inflammation of the kidney.
##STR00001##
STILBENE DERIVATIVE AND METHOD FOR PREPARING SAME
This invention relates to a stilbene derivative and a method of preparing the same, and more particularly to a novel stilbene derivative for inhibiting the function of cyclophilin, which is effective at the prevention of cyclophilin-related diseases or at the treatment of symptoms of such diseases, and to a method of preparing the same.
STILBENE DERIVATIVE AND METHOD FOR PREPARING SAME
This invention relates to a stilbene derivative and a method of preparing the same, and more particularly to a novel stilbene derivative for inhibiting the function of cyclophilin, which is effective at the prevention of cyclophilin-related diseases or at the treatment of symptoms of such diseases, and to a method of preparing the same.
BENZYL PHENYL ETHER DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USES THEREOF
The present invention discloses a benzyl phenyl ether derivative, a preparation method therefor, and a pharmaceutical composition and uses thereof. Specifically, the invention relates to benzyl phenyl ether derivatives represented by formula (I), a pharmaceutically-acceptable salt thereof, a stereoisomer thereof, a preparation method therefor, a pharmaceutical composition containing the one or more compounds, and uses of the compounds in treating diseases related to PD-1/PD-L1 signal channels, such as cancers, infectious diseases and autoimmune diseases.
##STR00001##
BENZYL PHENYL ETHER DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USES THEREOF
The present invention discloses a benzyl phenyl ether derivative, a preparation method therefor, and a pharmaceutical composition and uses thereof. Specifically, the invention relates to benzyl phenyl ether derivatives represented by formula (I), a pharmaceutically-acceptable salt thereof, a stereoisomer thereof, a preparation method therefor, a pharmaceutical composition containing the one or more compounds, and uses of the compounds in treating diseases related to PD-1/PD-L1 signal channels, such as cancers, infectious diseases and autoimmune diseases.
##STR00001##
PHENYLATE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USES THEREOF
The present invention discloses a phenylate derivative, a preparation method therefor, and a pharmaceutical composition and uses thereof. Specifically, the invention relates to phenylate derivatives represented by formula (I), a pharmaceutically-acceptable salt thereof, a stereoisomer thereof, a preparation method therefor, a pharmaceutical composition containing the one or more compounds, and uses of the compounds in treating diseases related to PD-1/PD-L1 signal channels, such as cancers, infectious diseases and autoimmune diseases.
##STR00001##
PYRROLIDINE DERIVATIVES AS PPAR AGONISTS
The present invention discloses a class of pyrrolidine derivatives as PPAR agonist, and their use for the treatment of some diseases of PPAR receptor-associated pathways (such as nonalcoholic steatohepatitis and concurrent fibrosis, insulin resistance, primary biliary cholgangitis, dyslipidenmia, hyperlipidemia, hypercholesterolemia, atherosclerosis, hypertriglyceridemia, cardiovascular disease, obesity or the like). In particular, the present invention discloses a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof.
##STR00001##